Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) Stock Short Interest Report for October

Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) saw a significant growth in short interest in October. As of October 15th, there was short interest totaling 2,971 shares, a growth of 193.6% from the September 30th total of 1,012 shares. Currently, 0.1% of the shares of the stock are sold short. Based on an average daily trading volume, of 31,943 shares, the short-interest ratio is currently 0.1 days.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Cardio Diagnostics in a report on Tuesday, September 8th. One analyst has rated the stock with a Sell rating. According to data from MarketBeat, Cardio Diagnostics has an average rating of “Sell”.

Institutional Investors Weigh In On Cardio Diagnostics

A hedge fund recently bought a new position in Cardio Diagnostics stock. Renaissance Technologies LLC bought a new stake in shares of Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 15,348 shares of the company’s stock, valued at approximately $30,000. Renaissance Technologies LLC owned approximately 0.52% of Cardio Diagnostics at the end of the most recent reporting period. Institutional investors own 8.06% of the company’s stock.

Cardio Diagnostics Price Performance

Cardio Diagnostics stock traded up $0.04 during mid-day trading on Thursday, hitting $1.74. The company’s stock had a trading volume of 3,853 shares, compared to its average volume of 1,232,469. The company has a market cap of $5.14 million, a PE ratio of -0.59 and a beta of 2.29. The firm’s 50 day moving average is $1.89 and its 200 day moving average is $2.07. Cardio Diagnostics has a 52-week low of $0.97 and a 52-week high of $7.91.

Cardio Diagnostics (NASDAQ:CDIO) last announced its quarterly earnings results on Friday, August 7th. The company reported ($0.51) EPS for the quarter. Cardio Diagnostics had a negative net margin of 43,133.33% and a negative return on equity of 82.28%. The firm had revenue of $0.01 million during the quarter.

Cardio Diagnostics Company Profile

Cardio Diagnostics Holdings, Inc is a biotechnology company developing artificial intelligence-powered precision medicine products for the prevention and management of cardiovascular disease. Its approach combines genetic, epigenetic and clinical information to help identify individuals at elevated risk and support more personalized care.

The company’s product portfolio includes Epi+Gen CHD, a blood-based test designed to assess an individual’s risk of developing coronary heart disease and provide information that may guide prevention strategies.